Physician profile
Corrie Hansen
NPI 1689284820
$4,427.50
in general payments reported to CMS, 2019-2025
21 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $709 · 2023: $931 · 2024: $794 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,260.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $967.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $438.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $339.79 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $302.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $249.81 | 2023-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.62 | 2025 | Caplyta |
| Pfizer INC. | $114.62 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.09 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $90.85 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $74.29 | 2023-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $72.61 | 2021-2022 | |
| Viatris Specialty LLC | $61.48 | 2025 | Yupelri |
| Mylan Specialty L.P. | $44.56 | 2021-2024 | Yupelri |
| Amarin Pharma, INC. | $39.70 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.61 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.31 | 2025 | Xifaxan |
| Averitas Pharma INC. | $18.13 | 2023 | Qutenza |
| Harmony Biosciences LLC | $16.54 | 2023 | Wakix |
| Arbor Pharmaceuticals, INC. | $11.52 | 2021 | |
| Cequr Corporation | $10.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.